02319nam a2200457 i 4500 278145 278145 on1078951640 OCoLC 20190121092913.0 m o d f cr bn||||a|||| 181214s2018 dcua ob f000 0 eng c PUCPR eng rda pn GPO MvI pcc n-us--- 1043-C (online) Y 4.L 11/4:S.HRG.114-805 Y 4.L 11/4:S.HRG.114-805 United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families, EpiPen price increases : how regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY). How regulatory barriers inhibit pharmaceutical competition Washington : U.S. Government Publishing Office, 2018. 1 online resource (iii, 43 pages) : illustrations. txt c rdamedia cr rdacarrier S. hrg. ; 114-805 CRDP Program record. Includes bibliographical references. Description based on online resource; title from PDF title page (govinfo web site, viewed on December 14, 2018). Print version: United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families. EpiPen price increases (OCoLC)1078409593 United States. Congress. Senate. S. hrg. ; 114-805. https://purl.fdlp.gov/GPO/gpo113215 KF26 .L2733 2016 Prescription pricing United States. Drugs Law and legislation United States. Pharmaceutical industry United States. Competition United States. Drug delivery devices Prices United States. Legislative hearings. lcgft sudocs 8 0 0 sudocs 0 Y_4L_114SHRG114805 0 403769 7 7 55 2019-01-21 0 Y 4.L 11/4:S.HRG.114-805 Y 4.L 11/4:S//INTERN 2019-01-21 00:00:00 1 2019-01-21 8